188 related articles for article (PubMed ID: 29966864)
1. Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.
Gu Y; Chow MJ; Kapoor A; Mei W; Jiang Y; Yan J; De Melo J; Seliman M; Yang H; Cutz JC; Bonert M; Major P; Tang D
Transl Oncol; 2018 Aug; 11(4):1012-1022. PubMed ID: 29966864
[TBL] [Abstract][Full Text] [Related]
2. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis.
Xie Y; Yan J; Cutz JC; Rybak AP; He L; Wei F; Kapoor A; Schmidt VA; Tao L; Tang D
Biochim Biophys Acta; 2012 Jun; 1822(6):875-84. PubMed ID: 22406297
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of FAM84B during prostate cancer progression.
Wong N; Gu Y; Kapoor A; Lin X; Ojo D; Wei F; Yan J; de Melo J; Major P; Wood G; Aziz T; Cutz JC; Bonert M; Patterson AJ; Tang D
Oncotarget; 2017 Mar; 8(12):19218-19235. PubMed ID: 28186973
[TBL] [Abstract][Full Text] [Related]
4. Effective Prediction of Prostate Cancer Recurrence through the
Gu Y; Lin X; Kapoor A; Li T; Major P; Tang D
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498739
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
[TBL] [Abstract][Full Text] [Related]
6. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of IQGAP2 Correlates with Prostate Cancer Recurrence and Metastasis.
Xie Y; Zheng L; Tao L
Transl Oncol; 2019 Feb; 12(2):236-244. PubMed ID: 30428404
[TBL] [Abstract][Full Text] [Related]
8. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
10. Physiological roles for butyrylcholinesterase: A BChE-ghrelin axis.
Brimijoin S; Chen VP; Pang YP; Geng L; Gao Y
Chem Biol Interact; 2016 Nov; 259(Pt B):271-275. PubMed ID: 26915976
[TBL] [Abstract][Full Text] [Related]
11. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
13. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo.
Baranowska-Kortylewicz J; Kortylewicz ZP; McIntyre EM; Sharp JG; Coulter DW
J Pediatr Hematol Oncol; 2022 Aug; 44(6):293-304. PubMed ID: 34486544
[TBL] [Abstract][Full Text] [Related]
14. FAM84B promotes prostate tumorigenesis through a network alteration.
Jiang Y; Lin X; Kapoor A; He L; Wei F; Gu Y; Mei W; Zhao K; Yang H; Tang D
Ther Adv Med Oncol; 2019; 11():1758835919846372. PubMed ID: 31205500
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin.
Seim I; Jeffery PL; de Amorim L; Walpole CM; Fung J; Whiteside EJ; Lourie R; Herington AC; Chopin LK
Reprod Biol Endocrinol; 2013 Jul; 11():70. PubMed ID: 23879975
[TBL] [Abstract][Full Text] [Related]
16. LEDGF gene silencing impairs the tumorigenicity of prostate cancer DU145 cells by abating the expression of Hsp27 and activation of the Akt/ERK signaling pathway.
Bhargavan B; Fatma N; Chhunchha B; Singh V; Kubo E; Singh DP
Cell Death Dis; 2012 May; 3(5):e316. PubMed ID: 22647853
[TBL] [Abstract][Full Text] [Related]
17. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.
Taylor RM; Severns V; Brown DC; Bisoffi M; Sillerud LO
Prostate; 2012 Apr; 72(5):523-32. PubMed ID: 21748756
[TBL] [Abstract][Full Text] [Related]
19. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
20. Periostin: a promising target of therapeutical intervention for prostate cancer.
Sun C; Zhao X; Xu K; Gong J; Liu W; Ding W; Gou Y; Xia G; Ding Q
J Transl Med; 2011 Jun; 9():99. PubMed ID: 21714934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
